Press Releases

Cytovance® Biologics Inc., Completes Its First FDA General Inspection Of Oklahoma City, OK Facilities.

Cytovance hosted an unannounced FDA inspection Tuesday, July 11th 2017.

Cytovance® Biologics Wins 2017 CMO Leadership Awards

Oklahoma City, OK – (March 14, 2017) Cytovance® Biologics, a leading CDMO who provides unparalleled support to biopharmaceutical companies to move candidate molecules from the bench to commercial manufacturing, announces today that it has received a CMO Leadership Award in three categories.

Cytovance® Biologics announces Michael O’Mara as Senior Vice President of Manufacturing Operations

Oklahoma City, OK – (January 13, 2017) Cytovance® Biologics, Inc., a leading full service biopharmaceutical contract manufacture of mammalian and microbial biologics, today announced the addition of Mike O’Mara as Sr. Vice President of Manufacturing Operations

OncoQuest Initiates Commercial Scale Oregovomab Manufacturing Program for Treatment of Ovarian Cancer

OncoQuest Inc. Signs Agreement with Cytovance for Development of Commercial Scale Antibody Manufacturing, and with Veristat for Clinical Trial Management

Cytovance Biologics, Inc. Announces New Hire Joyce Johnson as Vice President, Human Resource

OKLAHOMA CITY, OK --(Marketwired - November 29, 2016) - Cytovance® Biologics, Inc., a leading full service contract manufacturer of mammalian and microbial biologics, today announced the addition of Joyce Johnson as Vice President of Human Resources.

Cytovance Biologics Inc., Welcomes New Chief Financial Officer

Oklahoma City, OK – (September 13, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of Jenny Chen to Chief Financial Officer.

Cytovance Biologics, Inc., and Hepalink, Appoints Dr. Jesse McCool as New Board Member

Oklahoma City, OK – (August 9, 2016) Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing organization announces the appointment of a Dr. Jesse McCool to its Board of Directors

Cytovance Plans on expanding our track record for robust Microbial GMP products.

Cytovance® Biologics, Inc. a leading full service contract manufacturer of mammalian and microbial biologics announces expansion plans for Keystone Expression SystemTM.

BiondVax Pharmaceuticals Ltd. selects Cytovance® Biologics Inc. for the manufacturing of M-001 the universal flu…

Cytovance® Biologics, Inc. announced that it has entered into a Development and Manufacturing Agreement for the production of Phase III batches of a universal flu vaccine, M-001, with BiondVax Pharmaceuticals Ltd. (TASE, NASDAQ: BVXV), a biopharmaceutical company, based in Ness Ziona Israel.

Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc.

Cytovance® Biologics, Inc., announced today that they have entered into a definitive agreement by which Hepalink USA Inc. will acquire Cytovance® Biologics Inc., a leading biopharmaceutical contract development manufacturing company.

Cytovance® Biologics Inc. Announces Development & Manufacturing Deal With NeuroFx

Cytovance® Biologics, Inc., a leading full-service contract development and manufacturer of mammalian and microbial biologics, announces that it has teamed up with NeuroFx to develop and manufacture stem cell derived, cell-free therapy for neurological conditions.

Cytovance® Biologics Inc., Honored at 2015 CMO Leadership Awards

Oklahoma City, OK - Cytovance® Biologics Inc., a leader in the manufacturing of mammalian and microbial biopharmaceuticals announced it has received four CMO Leadership Awards for 2015

Cytovance® Biologics’ Jesse McCool, Ph.D., to present at 2015 BioInnovation Summit in London, UK

Oklahoma City, OK-Cytovance® Biologics, Inc., a leading biopharmaceutical contract manufacturing company is gearing up for The BioInnovation Summit in London, UK February 10-11, 2015. Jesse McCool, Ph.D., will present on one of Cytovance’s open innovation projects, the Keystone Expression System™

Cytovance® Biologics, Inc. Announces New Hire in R&D

Cytovance Biologics, Inc. is pleased to announce the appointment of Seth Fisher as Director of Purification Development in the R&D Services group.